GPER1 and endometrioid adenocarcinoma: GPR30 expression was observed in 75.4% (46/61) of serous adenocarcinomas, 83.3% (25/30) of endometrioid adenocarcinomas and 73.7% (14/19) of mucinous adenocarcinomas, while 20.7% (6/29) of clear cell carcinomas were observed to express the protein.